Literature DB >> 2594870

Haloperidol and reduced haloperidol plasma levels in Chinese vs. non-Chinese psychiatric patients.

M W Jann1, W H Chang, C M Davis, T Y Chen, H C Deng, F W Lung, L Ereshefsky, S R Saklad, A L Richards.   

Abstract

Haloperidol and reduced haloperidol plasma concentrations were measured in age-matched Chinese and non-Chinese patients (n = 32). Steady-state plasma concentrations were obtained 10-12 hours after the bedtime dose. Haloperidol and reduced haloperidol concentrations were measured by liquid chromatography and radioimmunoassay. Haloperidol plasma concentrations did not significantly differ between the populations, but reduced haloperidol levels were 3 times greater in non-Chinese patients than in Chinese patients. The incidence of extrapyramidal side effects was higher in Chinese patients (18 vs. 10), while non-Chinese patients with extrapyramidal symptoms had higher reduced haloperidol plasma levels. Logistic regression analysis revealed that ethnicity and reduced haloperidol/haloperidol ratios were important variables in predicting extrapyramidal symptoms. These results suggest that the metabolism and disposition of haloperidol and reduced haloperidol could differ among ethnic populations.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2594870     DOI: 10.1016/0165-1781(89)90170-4

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  11 in total

Review 1.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

Review 2.  Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment?

Authors:  W H Chang
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 3.  Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype.

Authors:  A Llerena; J Cobaleda; C Martínez; J Benítez
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

4.  A method to estimate in vivo D2 receptor occupancy by antipsychotic drugs.

Authors:  R A Roemer; E Richelson; C Shagass; L Leventhal
Journal:  J Psychiatry Neurosci       Date:  1996-11       Impact factor: 6.186

Review 5.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

6.  Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol.

Authors:  J G Shin; K Kane; D A Flockhart
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

Review 7.  Clinical trials and transethnic pharmacology.

Authors:  M E Kitler
Journal:  Drug Saf       Date:  1994-11       Impact factor: 5.606

Review 8.  Pharmacokinetics of haloperidol.

Authors:  J S Froemming; Y W Lam; M W Jann; C M Davis
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

Review 9.  Ethnic differences in the risks of adverse reactions to drugs used in the treatment of psychoses and depression: a systematic review and meta-analysis.

Authors:  Sara Ormerod; Sarah E McDowell; Jamie J Coleman; Robin E Ferner
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 10.  Pharmacokinetic optimisation of the treatment of psychosis.

Authors:  A E Balant-Gorgia; L P Balant; A Andreoli
Journal:  Clin Pharmacokinet       Date:  1993-09       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.